Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.41 |
| ▸ | GYS1 | P13807 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1448290 | 0.85 | GPR119 (0.67) | GPR119 | |
| SCHEMBL1447885 | 0.77 | GPR119 (0.67) | GPR119 | |
| SCHEMBL1447763 | 0.74 | GPR119 (0.70) | GPR119 | |
| SCHEMBL1447762 | 0.74 | GPR119 (0.70) | GPR119 | |
| SCHEMBL1448399 | 0.74 | GPR119 (0.67) | GPR119KITMMP13 | |
| SCHEMBL1449656 | 0.72 | GPR119 (0.47) | GPR119KMT2AMEN1SLC6A7 | |
| SCHEMBL28283417 | 0.69 | MCHR1 (0.56) | KMT2AHDAC6 | |
| SCHEMBL15578131 | 0.68 | ALKBH1 (0.53) | GPR119KITALKBH1MMP13KMT2A | |
| SCHEMBL10795881 | 0.67 | HDAC4 (0.54) | CYP11B2HDAC6 | |
| SCHEMBL1448573 | 0.67 | GPR119 (0.62) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011030139-A1 | 4- (PYRIMIDIN-2-YL) -PIPERAZINE AND 4- (PYRIMIDIN-2-YL) -PIPERIDINE DERIVATIVES AS GPR119 MODULATORS | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | WO | disclosed |
| US-20110065706-A1 | Therapeutic Agents 812 | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065706-A1 | Therapeutic Agents 812 | GPR119, GPR84, GPR132 | GPR119 1/4885KIT 1215/4885ALKBH1 4637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.